Pharmaceutical Executive September 2, 2025
Marc Stapley, CEO of Versyte, discusses new approaches to diagnostics and how its transforming cancer care.
Pharmaceutical Executive: How have recent developments in genomic research transformed cancer care?
Marc Stapley: There’s been a lot of change in diagnostics in general, but particularly in oncology over the last five years. It’s clear that next gen sequencing has created a new paradigm that has enabled us to come up with new tests and put them in clinical use. The way that the industry has transformed has gone from a model driven by volume (even if the test was painful) to a more responsible model that generates evidence in a way that ensure durable ongoing reimbursement for a test, having it released to the...
Today's Sponsors
Today's Sponsor